Retatrutide: What the Research Shows So Far
Quick answer
Retatrutide remains investigational, with ongoing trials assessing its benefits, risks and longer-term safety. The evidence is not yet complete, and it is not licensed or available at our clinics; products sold online are not approved alternatives.
Retatrutide is an investigational once-weekly medicine that activates GIP, GLP-1 and glucagon receptors. It has no UK marketing authorisation, cannot be prescribed by this clinic, and is not available as a treatment.
Why it attracts attention
Phase 2 research published in the New England Journal of Medicine reported large average weight reductions over 48 weeks, and later company-reported phase 3 findings have been broadly consistent. Averages of that size are notable, and they are also research averages in selected populations rather than predictions for an individual.
The glucagon component
Adding glucagon-receptor activity is what distinguishes retatrutide from GLP-1 and dual GIP/GLP-1 medicines. Glucagon activity may increase energy expenditure, and it also warrants careful evaluation of effects on heart rate, glucose regulation and liver parameters. This is precisely what full regulatory review examines.
Why topline results are not approval
Regulators assess complete efficacy and safety datasets, manufacturing quality and risk management. A press release, a conference presentation or a filing in another country tells you nothing definitive about UK availability or timing. There is no confirmed UK approval date.
The market that already exists
Retatrutide is sold illegally online as a research peptide. Those products are unregulated and may be counterfeit, contaminated, incorrectly dosed or non-sterile. We strongly advise against using them. There is no clinical oversight, no product liability and no way to verify what is in the vial.
What to do instead
If you want treatment now, licensed options exist and can be assessed properly. If you are specifically interested in retatrutide, participation should only be through a registered clinical trial centre. Both routes are safe. Buying peptides online is not.
Reviewed by
Dr Chinnadorai Rajeswaran
Specialist Endocrinologist · MBBS MRCP FRCP
Last Reviewed: November 2026
Read about complex severe obesity and related care.
Related insights
Weight Regain After GLP-1 Treatment: Why It Happens
Weight regain after stopping GLP-1 treatment is common because appetite and weight-regulating biology persist, though individual responses differ. Discuss a long-term plan with the prescriber before stopping or restarting, and do not alter doses independently.
Foundayo (Orforglipron): What a Daily Tablet Changes
Foundayo is a once-daily orforglipron tablet licensed in the UK, offering an oral route without the fasting routine required for oral semaglutide. Taking a tablet rather than an injection does not remove the need for a doctor to assess suitability, monitor side effects and review ongoing treatment.
Oral or Injectable GLP-1: How We Choose a Route
Oral and injectable GLP-1 medicines differ in absorption, dosing, evidence, and practical considerations; neither route is automatically best for everyone. A prescriber should choose based on the specific product, medical history, preferences, and local approval, with instructions followed exactly.